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To the Editor: We recently detected an alarming series of cases of suspected new 
diagnoses of inflammatory bowel disease (IBD) in patients receiving secukinumab. 
Secukinumab is an IL-17A neutralizing antibody widely used in dermatological and 
rheumatological diseases (1). 
In the last 6 months 5 patients were referred to our IBD ambulatory for evaluation of 
abdominal pain and diarrhea after receiving secukinumab and three of them were diagnosed 
with IBD.  Main features of the patients are reported in table 1. 
 
Table 1. 
   
The first patient was referred from another hospital for onset of bloody diarrhea after a 12-
month therapy with secukinumab for plaque psoriasis unresponsive to adalimumab and 
etanercept. A colonoscopy was performed showing an active inflammation of the rectum 
and sigmoid colon confirmed by crypt distortion and abscess seen through histological 
examination. Secukinumab was suspended and the patient was successfully treated with 
intravenous steroids. After three months their disease relapsed: a second colonoscopy was 
performed confirming the diagnosis of active extensive ulcerative colitis (UC). As psoriasis 
was worsening, the patient was evaluated both from gastroenterologist and dermatologist 
and we are planning to start ustekinumab soon. 
A second patient reported onset of non-bloody diarrhea and abdominal pain after 5-months 
of therapy with secukinumab for ankylosing spondylitis. A colonoscopy with histological 
examination showed a segmental chronical inflammation of the bowel, suggestive of IBD. 
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We decided to stop secukinumab administration and to prescribe systemic oral steroids. 
Three months later the patient was in clinical remission. 
Regarding patient 3, he was referred to us because of onset of IBD while undergoing 
secukinumab for psoriasis unresponsive to immunosuppressant and anti TNF drugs; he was 
first admitted to another hospital for non-bloody diarrhea, abdominal pain, vomiting and 
weight loss; the patient reported starting secukinumab three months before symptoms 
onset. Colonoscopy showed extensive colonic inflammation and histological examination 
was suggestive of IBD. After stopping secukinumab the patient was treated with adalimumab 
with no benefit. Due to the severe activity of both IBD and psoriasis we decided to start 
ustekinumab with good results on dermatological and gastroenterological symptoms. 
Although IL-17 is believed to be one of the pro-inflammatory cytokines involved in 
pathogenesis of IBD (2), a few cases of worsening or new onset of IBD in patients 
undergoing IL17A inhibitor have been reported (3, 4). Moreover, during secukinumab clinical 
trials on psoriasis 3 ulcerative colitis (UC) and 1 Crohn’s disease (CD) were reported among 
treatment group (whereas in the placebo group no cases of IBD were detected) (5).  
The IBD incidence seen in these studies may in part be related to the underlying correlation 
between IBD and psoriasis, psoriatic arthritis and ankylosing spondylitis, but the possibility 
that IBD is an adverse effect of the biologic itself cannot be excluded. This arouses important 
thoughts about the etiopathogenesis of IBD: the complete block of the action of IL-17A could 
contribute to the leaky intestinal epithelium found in IBD (3)? 
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Table 1. Characteristics of the patients  
 
AGE SEX DISEASE FAMILY 
HISTORY 
OF IBD? 
SMOKER? GI SYMPTOMS 
BEFORE 
SECUKINUMAB? 
HISTOLOGI
CALLY 
CONFIRMED 
IBD? 
27 F Plaque 
psoriasis 
no no  no  Yes  
46 F Ankylosing 
spondylitis 
no no no  Yes  
33 M Psoriatic 
arthritis 
no                no no  Yes  
 
F = female; M = male 
